Loading...
Millions of people worldwide are coinfected with tuberculosis (TB) and HIV. For those who require concomitant treatment but cannot receive NNRTIs (e.g., because of intolerance or resistance), options are extremely limited. Standard-dose PIs cannot be coadministered with rifampin because plasma levels of the antiretroviral are reduced by 70% to 90% in this setting, rendering the drug ineffective.
In this pharmacokinetic study, researchers sought to evaluate the effect of rifampin on adjusted dosages of lopinavir/ritonavir in the tablet formulation. The study design called for 40 healthy volunteers to receive rifampin alone for 5 days and then with lopinavir/r (600/150 mg twice daily or 800/200 mg twice daily) for 10 days. However, the study w…